Drug Type Biosimilar, Monoclonal antibody |
Synonyms Omalizumab biosimilar, Xolair biosimilar, Xolair biosimilar-Celltrion + [3] |
Target |
Mechanism IgE inhibitors(Immunoglobulin E inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date EU (16 May 2024), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Allergic asthma | EU | 16 May 2024 | |
Allergic asthma | IS | 16 May 2024 | |
Allergic asthma | LI | 16 May 2024 | |
Allergic asthma | NO | 16 May 2024 | |
Chronic rhinosinusitis with nasal polyps | EU | 16 May 2024 | |
Chronic rhinosinusitis with nasal polyps | IS | 16 May 2024 | |
Chronic rhinosinusitis with nasal polyps | LI | 16 May 2024 | |
Chronic rhinosinusitis with nasal polyps | NO | 16 May 2024 | |
Chronic Urticaria | EU | 16 May 2024 | |
Chronic Urticaria | IS | 16 May 2024 | |
Chronic Urticaria | LI | 16 May 2024 | |
Chronic Urticaria | NO | 16 May 2024 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Asthma | NDA/BLA | US | 10 Mar 2024 | |
Food Hypersensitivity | NDA/BLA | US | 10 Mar 2024 | |
Urticaria | Phase 3 | PL | - |
Phase 1 | - | 176 | (CT-P39 (Part 2)) | wtmtfmlodi(pcufezyunz) = zkqcedjzma uisvroizgn (kudzknnjni, vsmiggpfsl - wxvbctmoel) View more | - | 11 May 2023 | |
(EU-approved Xolair (Part 2)) | wtmtfmlodi(pcufezyunz) = mgvwmniukl uisvroizgn (kudzknnjni, tstlbjoutb - tsbnbfyfqd) View more | ||||||
NCT04018313 (Pubmed) Manual | Phase 1 | - | 146 | smadjrfshn(ozfsdycjve) = there were no treatment-related serious adverse events jsbnsivzmi (acvurwjnvy ) | Positive | 01 Nov 2022 | |